Mainz Biomed to Present Results of Pancreatic Cancer Verification Study at AACR 2026 Annual Meeting

Rhea-AI Summary

Mainz Biomed (NASDAQ: MYNZ) will present initial verification results of a blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and differentiation of intraductal papillary mucinous neoplasms (IPMN) at the AACR 2026 Annual Meeting in San Diego, April 17–22, 2026.

The presentation covers a 30-subject verification study using a compact proprietary panel of blood-derived mRNA biomarkers combined with an AI-assisted modeling approach to distinguish PDAC from benign conditions including IPMN. Further details are slated for the online Proceedings of AACR.

News Market Reaction – MYNZ

%

2 alerts

% News Effect

-5.0% Trough Tracked

$11M Market Cap

0.8x Rel. Volume

On the day this news was published, MYNZ declined NaN%, reflecting a moderate negative market reaction. Argus tracked a trough of -5.0% from its starting point during tracking. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Study cohort size: 30 subjects Conference dates: April 17–22, 2026

2 metrics

Study cohort size 30 subjects Verification study differentiating PDAC from benign conditions including IPMNs

Conference dates April 17–22, 2026 AACR 2026 Annual Meeting presentation timing

Market Reality Check

Price: $0.7600 Vol: Volume 362,571 is below t...

normal vol

$0.7600 Last Close

Volume Volume 362,571 is below the 20-day average of 435,863 (relative volume 0.83x). normal

Technical Shares at $1.12 are trading below the $1.81 200-day moving average and 86.34% below the 52-week high.

Peers on Argus

MYNZ was down 4.27% pre-news. Peers showed mixed moves: BIAF (-3.1%), ADVB (-0.9...

1 Down

MYNZ was down 4.27% pre-news. Peers showed mixed moves: BIAF (-3.1%), ADVB (-0.9%), XWEL (-2.61%) declined, while ISPC (11.7%) and CHEK (2.55%) rose; only ISPC appeared in momentum scanners, moving down 6.33% without news.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Year review update	Positive	+9.5%	Review of 2025 clinical, regulatory, partnership and funding milestones.
Dec 02	Distribution partnership	Positive	+2.6%	ColoAlert added to DoctorBox digital health portfolio in Germany.
Nov 18	South America expansion	Positive	-4.8%	MOU to introduce ColoAlert in South American markets starting with Peru.
Nov 12	Conference showcase	Positive	+4.6%	Showcased ColoAlert and early-stage diagnostics at MEDICA 2025.
Nov 10	Medical meeting attendance	Positive	+0.8%	Participation at GARPS meeting to present ColoAlert and pipeline.

Pattern Detected

Recent company announcements have usually coincided with modest positive price reactions, with one notable divergence where a partnership headline saw a negative move.

Recent Company History

Over the last few months, Mainz Biomed highlighted multiple commercial and clinical milestones. On Jan 5, 2026, it reviewed 2025 progress, including strong colorectal and pancreatic test performance, and the stock rose 9.48%. Earlier, ColoAlert distribution expanded via DoctorBox on Dec 2, 2025 and into South America via an MOU on Nov 18, 2025. Presence at MEDICA 2025 and the GARPS meeting in November 2025 showcased its diagnostics portfolio. Today’s AACR pancreatic verification study presentation continues this trajectory in early cancer detection.

Regulatory & Risk Context

Active S-3 Shelf · $150,000,000

Shelf Active

Active S-3 Shelf Registration 2025-12-05

$150,000,000 registered capacity

An effective Form F-3 shelf filed on Dec 5, 2025 allows Mainz Biomed to offer up to $150,000,000 in securities, subject to limits of no more than one-third of public float in any 12-month period until its non-affiliate market value exceeds $75,000,000. Proceeds are expected to be used for working capital, providing flexibility for future financings.

Market Pulse Summary

This announcement highlights upcoming AACR 2026 data from a 30-subject verification study using bloo...

Analysis

This announcement highlights upcoming AACR 2026 data from a 30-subject verification study using blood-based mRNA biomarkers and AI-assisted modeling to differentiate PDAC from benign conditions including IPMNs. It follows recent progress across ColoAlert and the PancAlert program. With an effective Form F-3 shelf for up to $150,000,000 in securities, future financing activity remains a key factor to watch alongside further clinical readouts and commercial execution in colorectal and pancreatic cancer diagnostics.

Key Terms

pancreatic ductal adenocarcinoma, PDAC, intraductal papillary mucinous neoplasms, IPMN, +2 more

6 terms

pancreatic ductal adenocarcinoma medical

"blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection"

A fast-growing cancer that starts in the cells lining the pancreas’ small ducts; it is the most common and aggressive form of pancreatic cancer. It matters to investors because its severity and limited treatment options drive high unmet medical need, large potential markets for effective drugs or diagnostics, and strong sensitivity of company valuations to clinical trial results, regulatory approvals, or changes in treatment guidelines—similar to how fixing a main leak can prevent major damage in a building.

PDAC medical

"designed to differentiate PDAC from benign conditions including IPMNs"

PDAC stands for pancreatic ductal adenocarcinoma, the most common and aggressive form of pancreatic cancer that starts in the pancreas’s duct cells. It matters to investors because PDAC represents a large unmet medical need with high patient mortality, driving intense drug development, clinical trial activity and potential regulatory milestones—like a critical, hard-to-fix engine part whose failure creates urgent demand for effective solutions, affecting a company’s valuation and risk profile.

intraductal papillary mucinous neoplasms medical

"detection and intraductal papillary mucinous neoplasms (IPMN) differentiation"

Noncancerous or pre-cancerous growths that form in the mucus-producing ducts of the pancreas; they can stay harmless or develop into pancreatic cancer over time, so doctors monitor them closely. Think of them like corrosion inside a pipe: small spots may be watched, but if they start spreading or causing blockage, they require repair. For investors, their presence drives demand for diagnostic tests, drugs, and surgical or imaging technologies, influences clinical trial design and regulatory decisions, and shapes market opportunities and health-care costs related to pancreatic disease.

IPMN medical

"differentiate PDAC from benign conditions including IPMNs in a 30-subject cohort"

Intraductal papillary mucinous neoplasm (IPMN) is a mucus‑producing growth that forms inside the ducts of the pancreas, often behaving like a slow‑growing fluid‑filled bubble that can remain harmless or gradually become malignant. It matters to investors because IPMNs can lead to pancreatic cancer or require ongoing monitoring, advanced imaging, biomarker testing, surgery, or new therapies, creating demand and risk factors for companies in diagnostics, treatment development and hospital services.

mRNA biomarkers medical

"compact proprietary combination of blood-derived mRNA biomarkers and an AI-assisted"

mRNA biomarkers are fragments of messenger RNA whose presence or level in tissue or blood acts like a biological dashboard indicator, signaling a disease state, how a patient is responding to treatment, or whether a drug is hitting its target. For investors, they matter because they can guide which patients will benefit from a therapy, improve success rates and speed of clinical trials, enable diagnostic products, and create new revenue streams tied to precision medicine.

AI-assisted modeling technical

"mRNA biomarkers and an AI-assisted modeling approach designed to differentiate PDAC"

AI-assisted modeling uses artificial intelligence tools to help build, test and refine mathematical representations of businesses, markets, financial forecasts, risk models or valuation analyses, combining computer pattern-finding with human judgment and domain rules. For investors it can speed analysis, uncover hidden correlations or risks and improve forecasting much like a smart co-pilot guiding a driver, but its outputs still need human review to avoid errors, bias or overconfidence.

AI-generated analysis. Not financial advice.

First data on blood-based mRNA signature for pancreatic ductal adenocarcinoma (PDAC) detection and intraductal papillary mucinous neoplasms (IPMN) differentiation to be presented in San Diego

BERKELEY, Calif. and , Jan. 14, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ: MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, is excited to announce its participation in the upcoming American Association for Cancer Research (AACR) 2026 Annual Meeting. This prestigious conference will be held April 17 to 22, 2026, in San Diego, California. Organized by the American Association for Cancer Research, this premier event gathers scientists, clinicians, and industry leaders from around the world to share groundbreaking cancer research and explore new approaches in oncology.

At AACR the Company will present the results of its verification study evaluating a compact proprietary combination of blood-derived mRNA biomarkers and an AI-assisted modeling approach designed to differentiate PDAC from benign conditions including IPMNs in a 30-subject cohort.

Further details will be published in the online Proceedings of the AACR.

The Company looks forward to present the results of this study at AACR as it aims to revolutionize pancreatic cancer screening practices and contribute to a reduction in cancer mortality rates worldwide.

Please visit Mainz Biomed’s official website for investors at mainzbiomed.com/investors/ for more information

Please follow us to stay up to date:
LinkedIn
X (Previously Twitter)
Facebook

About Mainz Biomed NV

Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company’s flagship product is ColoAlert^®, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer. ColoAlert^® is marketed across Europe. The Company is currently running its eAArly DETECT 2 clinical study in preparation for its pivotal FDA study for US regulatory approval. Mainz Biomed’s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in blood and stool samples. To learn more, visit mainzbiomed.com or follow us on LinkedIn, Twitter and Facebook.

For media inquiries as to Mainz Biomed:
MC Services AG
Maximilian Schur / Simone Neeten
+49 211 529252 20
mainzbiomed@mc-services.eu

For investor inquiries, please contact ir@mainzbiomed.com

Forward-Looking Statements

Certain statements made in this press release are “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company’s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the “SEC”) by the Company. Additional information concerning these and other factors that may impact the Company’s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on March 31, 2025 and its mid-year report on Form 6-K filed on September 26, 2025. The Company’s SEC filings are available publicly on the SEC’s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.

FAQ

When will Mainz Biomed (MYNZ) present its PDAC verification study at AACR 2026?

Mainz Biomed will present at the AACR 2026 Annual Meeting, April 17–22, 2026, in San Diego.

What did MYNZ present about pancreatic cancer detection at AACR 2026?

Results from a 30-subject verification study of a blood-based mRNA signature and AI-assisted model to differentiate PDAC from benign conditions including IPMN.

How large was the cohort in Mainz Biomed's AACR 2026 verification study (MYNZ)?

The verification study evaluated a cohort of 30 subjects.

Will Mainz Biomed publish the AACR 2026 presentation details for MYNZ?

Yes; further details will be published in the online Proceedings of AACR.

What technology did MYNZ use in the pancreatic cancer verification study?

A proprietary compact panel of blood-derived mRNA biomarkers combined with an AI-assisted modeling approach.

Where can investors find more information about Mainz Biomed (MYNZ) and the AACR presentation?

Investors can visit Mainz Biomed's investor site at mainzbiomed.com/investors/ for updates and presentation access details.